Improved Quality Care

The Challenge

There remains considerable variation in the management of lung cancer around the world.  Access for patients to important diagnostics, treatments and support programs varies markedly.

Our solution

ILC2: Initiatives in Lung Cancer Care, a Global Funding Opportunity to Transform Patient Care and Improve the Patient Experience

The ILC2 program supports patient and caregiver organizations registered as non-profit in their country to propose and conduct projects that can potentially transform patient care in countries around the world.

The program recognizes the high variation in lung cancer management around the world, and the very specific local barriers to quality care that must be considered when developing patient centric solutions to address them.

Round 2 Grantees are Now Announced

ILC2 grant applications are reviewed and selected by the four founding partners of the Lung Ambition Alliance: the Global Lung Cancer Coalition, Guardant Health, the International Association for the Study of Lung Cancer and AstraZeneca. Funding for the ILC2 grant is provided by AstraZeneca.


Disclaimer: Grants funding is open to any charitable and registered non-profit organizations involved in the care of patients with lung cancer.  The Grants process is supported by the Charities Aid Foundation (CAF).  When applying, applicants will be directed to CAF’s carefully selected service provider (Buzzacott) to enter your details. Data provided will only be used for the purposes of assessing your organisation's suitability for this program and to inform you of related services provided by Charities Aid Foundation (CAF) and its partners, where such consent has been provided. Please refer to the Privacy Policies of CAF and Buzzacott for more information on how any data provided will be used.


  1. World Health Organization. International Agency for Research on Cancer. Fact Sheet – Lung Cancer. Available at Accessed August 2019
  2. EpiCast Report: NSCLC Epidemiology Forecast to 2025. GlobalData. 2016.
  3. Cancer.Net. Lung Cancer - Non-Small Cell - Statistics. Available at Accessed May 2019
  4. Yousaf-Khan U, et al. Final Screening Round of the NELSON Lung Cancer Screening Trial: The Effect of a 2.5-year Screening Interval. Thorax. 2017;72:48–56.
  5. The National Lung Screening Trial Research Team. Reduced Lung-cancer Mortality with Low-dose Computed Tomographic Screening. N Engl J Med. 2011;365(5):395–409.
  6. Midthun D. Early detection of lung cancer. F1000Research. 2016;5(F1000 Faculty Rev):739
  7. NICE. The diagnosis and treatment of lung cancer (update). Available at Accessed August 2019
  8. Mathur S, et al. Personalised medicine could transform health care. Biomed Rep. 2017; (1) 3-5
  9. Jones G, et al. Recent advances in the management of lung cancer. Clinical Medicine. 2018;18(2):s41–s6
  10. Jemal a & Fedewa SA. Lung Cancer Screening With Low-Dose Computed Tomography in the United States—2010 to 2015. JAMA Oncol. 2017;3(9):1278-1281
  11. IASLC Successfully Pilots Early Lung Imaging Confederation Project. Available at Accessed August 2019
  12. Giroux, DJ et al. The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. Journal of Thoracic Oncology. 2018;13(6):801-809
  13. Jones G, et al. Recent advances in the management of lung cancer. Clinical Medicine. 2018;18(2):s41–s6
  14. Mascaux C, et al. Personalised medicine for nonsmall cell lung cancer. European Respiratory Review. 2017;26
  15. IASLC Pathology Committee. Available at Accessed August 2019